Reply to: Interpreting ctDNA-Guided Risk Stratification After First-Line Therapy

Key Points

• Clarify findings related to ctDNA-guided risk stratification and its implications in lymphoma treatment.
• Discussed the role of ctDNA in assessing minimal residual disease.
• Highlighted phased variants in the context of large B-cell lymphoma.
• Outlined areas needing further investigation.
• Confirmed the significance of ctDNA in monitoring disease status post-therapy.
• Indicated potential improvements in risk stratification methods for better patient outcomes.